Ascrinvacumab

{
  "id": "MLC-T-ONC-011247",
  "term": "Ascrinvacumab",
  "field": "Oncology and biomedicine",
  "definition": "A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, ascrinvacumab targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.",
  "synonyms": [
    "anti-activin receptor-like kinase 1 monoclonal antibody PF-03446962",
    "anti-activin receptor-like kinase-1 monoclonal antibody GT90001",
    "anti-ALK-1 monoclonal antibody GT90001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ascrinvacumab/"
}